Endocyte (ECYT) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.25 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.26. During the same quarter in the previous year, the company posted $-0.25 EPS.
Endocyte closed down -0.13 points or -4.09% at $3.05 with 2,08,872 shares getting traded on Tusday. Post opening the session at $3.18, the shares hit an intraday low of $3.02 and an intraday high of $3.18 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on May 12, 2016, Philip S Low (Chief Science Officer) purchased 11,375 shares at $3.52 per share price. According to the SEC, on Jan 20, 2016, Fred A Middleton (director) purchased 30,000 shares at $2.80 per share price. On Mar 5, 2015, Binh Nguyen (VP of Medical Affairs) sold 29,883 shares at $5.79 per share price, according to the Form-4 filing with the securities and exchange commission.
Endocyte Inc. (Endocyte) is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases. The Company’s pipeline includes: Vintafolide (Vynfinit or EC145) which delivers potent vinca alkaloid chemotherapy directly to cancer cells by targeting the folate receptor expressed on cancer cells but not on most normal cells; Folate-Tubulysin (EC1456) an SMDC (small molecule drug conjugates) consisting of folate (vitamin B9) linked to a potent cytotoxic agent tubulysin B hydrazide (TubBH); EC0652 a prostate-specific membrane antigen (PSMA)-targeted molecular imaging agent; EC1169 an investigational injectable PSMA-targeted SMDC; Etarfolatide (Folcepri or EC20) a folate-targeted molecular imaging agent; EC1669 a new approach to inflammation therapy targeting an anti-folate drug to activated macrophages expressing folate receptors; EC0371 a folate-targeted water-soluble form of rapamycin and EC1788 a Folate-targeted SMDC.